公司資料
Kezar Life Sciences 股價、新聞與催化劑
- 股票代碼:
- KZR
- 交易所:
- NASDAQ
- 產業:
- Life Science Tools
- 所在地:
- United States
股票表現
7.29 USD (-0.95%)
收盤價
最後更新: 2026年5月8日
53.9M USD
市值
股價為何變動
Current closing-price context is not available for KZR.
公司概覽
業務概覽
Kezar Life Sciences is a biotechnology company focused on immune pathways in autoimmune disease and oncology. Its strategy has centered on selective small-molecule biology and translational proof.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, Kezar sits in specialty biotechnology.
商業模式特徵
The business depends on clinical data, target validation, and the possibility of building a differentiated immune-modulation platform.
生技產業定位
Kezar is a catalyst-sensitive immunology name whose stock is driven by proof-of-concept and strategic updates.
未來催化劑
- Kezar’s catalysts are zetomipzomib and the remaining immunology pipeline, where the next update matters because the market needs a clearer read on what still has value. The company is in a reset phase, so strategic clarity matters as much as data.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。